论文部分内容阅读
本文将39例川崎病分为三组;即A组采用为阿斯匹林(ASA)治疗,B组采用为大剂量静脉注射用免疫球蛋白(IVIG)400mg/kg/天×5天治疗,C组采用IVIG2g/kg或1g/kg一次静注治疗。且B、C两组同时按A组ASA口服疗法。结果表明:在平均住院时间、热程、冠状动脉损害等方面B组和C组优于A组,C组优于B组。因此,在KD急性期尽早使用大剂量IVIG2g/kg或IVIG1g/kg一次静注疗法,同时应用ASA口服。
In this paper, 39 cases of Kawasaki disease were divided into three groups: group A was treated with aspirin (ASA), group B was treated with intravenous immunoglobulin (IVIG) 400 mg / kg / day × 5 days, Group C was treated with IVIG2g / kg or 1g / kg once intravenously. And B, C two groups at the same time by ASA oral therapy. The results showed that group B and group C were better than group A in terms of average length of stay, thermal history, and coronary artery damage, while group C was superior to group B. Therefore, high-dose IVIG2g / kg or IVIG1g / kg bolus therapy should be given as early as possible during the acute phase of KD with ASA administered orally.